Letters of Intent (LOIs) for 2021 OCRA scientific grant awards are now open for submission! Please visit the proposalCENTRAL grant portal to apply. LOI’s are due July 10, 2020. For questions regarding your application, please refer to our Grant Application FAQs. Additional questions may be sent via email to email@example.com.
- Collaborative Research Development Grants ($900,000) Click here to read the RFA.
- Liz Tilberis Early Career Awards ($450,000) Click here to read the RFA.
- Ann and Sol Schreiber Mentored Investigator Award ($75,000) Click here to read the RFA.
Launched in 2004, this grant provides funds for large ovarian cancer research projects that involve several investigators within one institution or collaborations between groups in multiple institutions. Support of $300,000 annually for three years will be awarded to the institution(s) in which the recipients will conduct the research.
Launched in December 2000, the Liz Tilberis Early Career Award is for junior faculty (Assistant Professor level) with a strong commitment to an investigative career in ovarian cancer research. Each grantee will receive a three-year grant of $150,000 per year. The program honors OCRA’s late president, Liz Tilberis.
The Ann and Sol Schreiber Mentored Investigator Award provides funding for trainees (post-doctoral fellows or clinical fellows) who are working under the supervision of a mentor who is a recognized leader in the field of ovarian cancer research. Applicants must have an MD or a PhD degree. The award provides a total of $75,000 to be used over one or two years, and will encourage the recipient’s research career in the field of ovarian cancer. This grant is named in honor of Ann and Sol Schreiber, OCRA's founders.
From 1998 – 2007, OCRF offered Individual Investigator Awards to advance outstanding early career researchers whose projects focused on early detection, screening, and basic translational research. These $100,000 grants were intended to yield results within two years or less. The ultimate aim of the program was to enable investigators, with promising results in hand, to obtain grants from the National Cancer Institute or other large funding agencies.